Adage Capital Partners Gp, L.L.C. An2 Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51 Billion
- Q1 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 312,615 shares of ANTX stock, worth $656,491. This represents 0.0% of its overall portfolio holdings.
Number of Shares
312,615
Previous 900,672
65.29%
Holding current value
$656,491
Previous $18.5 Million
94.5%
% of portfolio
0.0%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding ANTX
# of Institutions
55Shares Held
13.2MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.56MShares$3.27 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$3.27 Million0.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.39MShares$2.92 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA1.24MShares$2.6 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X01.22MShares$2.56 Million0.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $40.7M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...